These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 8606262

  • 1. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
    Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL.
    J Am Coll Cardiol; 1996 Mar 01; 27(3):536-42. PubMed ID: 8606262
    [Abstract] [Full Text] [Related]

  • 2. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep 02; 96(5):1445-53. PubMed ID: 9315530
    [Abstract] [Full Text] [Related]

  • 3. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Gibson CM, Goel M, Cohen DJ, Piana RN, Deckelbaum LI, Harris KE, King SB.
    J Am Coll Cardiol; 1998 Jul 02; 32(1):28-34. PubMed ID: 9669245
    [Abstract] [Full Text] [Related]

  • 4. Tirofiban. A review of its use in acute coronary syndromes.
    McClellan KJ, Goa KL.
    Drugs; 1998 Dec 02; 56(6):1067-80. PubMed ID: 9878994
    [Abstract] [Full Text] [Related]

  • 5. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
    Bonz AW, Lengenfelder B, Strotmann J, Held S, Turschner O, Harre K, Wacker C, Waller C, Kochsiek N, Meesmann M, Neyses L, Schanzenbächer P, Ertl G, Voelker W.
    J Am Coll Cardiol; 2002 Aug 21; 40(4):662-8. PubMed ID: 12204495
    [Abstract] [Full Text] [Related]

  • 6. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 7. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement.
    Juergens CP, White HD, Belardi JA, Macaya C, Soler-Soler J, Meyer BJ, Levy RD, Bunt T, Menten J, Herrmann HC, Adgey AA, Tarnesby G.
    Clin Ther; 2002 Aug 01; 24(8):1332-44. PubMed ID: 12240783
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
    Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1488-97. PubMed ID: 9599103
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 17; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
    Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators.
    N Engl J Med; 1998 May 21; 338(21):1498-505. PubMed ID: 9599104
    [Abstract] [Full Text] [Related]

  • 17. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators.
    JAMA; 2003 Feb 19; 289(7):853-63. PubMed ID: 12588269
    [Abstract] [Full Text] [Related]

  • 18. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 19. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH, Harrington RA.
    Drugs; 1998 Dec 20; 56(6):965-76. PubMed ID: 9878986
    [Abstract] [Full Text] [Related]

  • 20. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.
    Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R.
    J Am Coll Cardiol; 2004 Jul 07; 44(1):14-9. PubMed ID: 15234398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.